Last reviewed · How we verify
Gestational trophoblastic neoplasia
Approved treatments
- Vinblastin · The Lymphoma Academic Research Organisation
- Cosmegen · Recordati
Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Gestational trophoblastic neoplasia patent landscape — cliff calendar, originator estates, attackable patents
- Gestational trophoblastic neoplasia treatment landscape brief
- Gestational trophoblastic neoplasia treatment updates RSS
Frequently asked questions about Gestational trophoblastic neoplasia
What drugs treat Gestational trophoblastic neoplasia?
Tracked treatments include Vinblastin, Cosmegen, Trexall, Methotrexat.
What is the treatment for Gestational trophoblastic neoplasia?
Standard treatment for Gestational trophoblastic neoplasia includes Vinblastin, Cosmegen, Trexall, Methotrexat. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Gestational trophoblastic neoplasia patent cliff · Gestational trophoblastic neoplasia CI report
- Treatment: Vinblastin · The Lymphoma Academic Research Organisation
- Treatment: Cosmegen · Recordati
- Treatment: Trexall · Generic (originally Lederle Laboratories)
- Treatment: Methotrexat · Biocad
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing